Form 4: Castle Biosciences CCO Sells 700 Shares Under 10b5-1 Plan

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, sold 700 shares of common stock for approximately $24,773 under a pre-arranged 10b5-1 trading plan.

Summary

• Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, Inc. (CSTL), reported the sale of 700 shares of common stock.
• The transactions occurred on November 11, 2025, and November 12, 2025.
• On November 11, 2025, 500 shares were sold at a weighted-average price of $35.39 per share.
• On November 12, 2025, 200 shares were sold at a price of $35.40 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Juvenal on September 11, 2024.
• Following these transactions, Mr. Juvenal directly beneficially owns 83,827 shares and indirectly owns 2,230 shares through a family revocable trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information. It's a routine personal financial management event.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived as a slight negative signal regarding management's long-term outlook, though less so than unplanned sales.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing and does not provide specific industry context. Insider sales under 10b5-1 plans are common across various industries as executives manage personal finances and diversify holdings.

Related Party Transactions

• The indirect beneficial ownership of 2,230 shares is held by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the reporting person and his spouse are trustees and beneficiaries.

Stakeholder Impact

• Shareholders may view the insider sale, even if planned, with slight caution, though the impact is minimal given the small number of shares relative to total outstanding shares and the pre-arranged nature of the sale.

Key Dates

Recommendation

The filing details a routine insider sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or performance. Therefore, it does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on existing company fundamentals.

Keywords

Castle Biosciences, CSTL, Form 4, Insider Trading, Stock Sale, Tobin W. Juvenal, Chief Commercial Officer, 10b5-1 Plan, Equity Transaction